Measles, Mumps, Rubella Vaccine Market - By Vaccines Type, By Targeted Population, By End Use – Global Forecast, 2025 - 2034

Measles, Mumps, Rubella Vaccine Market Size

The global measles, mumps, rubella vaccine market size was estimated at USD 2 billion in 2024. The market is expected to grow from USD 2.1 billion in 2025 to USD 4.3 billion in 2034, at a CAGR of 8.3% during the forecast period. The measles, mumps, rubella (MMR) vaccine market continues to grow due to increased childhood immunization efforts, resurgence of outbreaks, and global public health initiatives.
 

The World Health Organization (WHO) reported over 10.3 million measles cases and 107,500 related deaths globally in 2023, marking a sudden increase due to disrupted immunization services during the COVID-19 pandemic. Additionally, mumps and rubella are still a matter of concern in the lower-middle-income countries because of the lack of resources and funding, which makes it necessary to act through vaccination programs that put an emphasis on the need for immunization.
 

Further, the market is bolstered by increased government spending on mass vaccination campaigns aimed at achieving herd immunity, especially in developing regions. Advancements in vaccine development such as combination vaccines and thermostable vaccines are lessening reliance on the cold chain, improving logistics, and increasing efficacy in distant and underserved areas.
 

Moreover, the global vaccination awareness, MMR vaccine healthcare, and infrastructure accessibility are increasing regionally, bolstering immunization rates. The increased birth rate of emerging economies and the inclusion of the MMR vaccine in routine immunization programs continues to broaden the target population. The new robust trivalent and quadrivalent vaccines for better control of the diseases are also aiding market growth.
 

The increase in adult immunization, especially among travelers and healthcare workers, is also creating secondary demand. The emergence of AI-driven vaccine research platforms and real-time epidemiological tracking is also supporting more targeted vaccine deployment. Regulatory approvals paired with continuous investment into research and development by pharmaceutical companies are bound to expand the presence of vaccines in the market, thereby ensuring considerable growth in the long run.
 

The measles, mumps, and rubella (MMR) vaccine market refers to the global industry involved in developing, manufacturing, and distributing combination vaccines that protect against these three infectious diseases. It includes public immunization programs, private healthcare demand, regulatory frameworks, and ongoing efforts to expand vaccination coverage, especially in developing countries.
 

Measles, Mumps, Rubella Vaccine Market Trends

• The market for the MMR vaccine is expanding noticeably due to greater participation in immunization programs, repeated outbreaks in developed and developing countries, and vigorous government efforts to remove vaccine-preventable illnesses from the population.
   
• The resurgence of measles on a global scale has significantly increased the demand for MMR vaccines. According to WHO, measles cases surged by over 79% globally in 2023 compared to the previous year, with over 306,000 reported cases and a growing trend in vaccine hesitancy worsening the situation.
   
• Mumps outbreaks have also contributed to market expansion. WHO reported that there are over 387,529 mump cases around the world in 2023. Outbreaks are often sustained in close contact settings such as colleges and military areas which contribute to the further spread of these infections.
   
• Even though rubella is less common, it can still be exceptionally harmful to pregnant women and newborn children. There is growing concern about congenital rubella syndrome (CRS) in parts of the world where immunization is not widely available.
   
• According to WHO, Rubella is the leading vaccine-preventable cause of birth defects, accounting for an estimated 100,000 infants born with CRS each year worldwide. Even though a safe and cost-effective vaccine is available, in 2022, WHO reported 17,865 cases of rubella in 78 countries.
   
• Further, the combination of increasing birth rates in developing countries and global initiatives to improve childhood vaccination coverage is driving the need for MMR combination vaccines. UNICEF and Gavi, the Vaccine Alliance have greatly increased access to vaccinations, distributing over 2 billion doses around the world every year.
   
• MMR disease transmission has increased due to urban migration and cross-border travel, mainly in areas with low vaccination coverage. Outbreaks of MMR in Europe and Southeast Asia has led to the implementation of special vaccination programs and increased procurement of MMR vaccine stockpiles.
   
• Strong and consistent investment as well as evolving technology in cold-chain or stem-free delivery mechanisms are increasing the deployment and acceptance of vaccine in in remote and underserved areas, impacting the entire market.
   
• Several regulators including the U.S. FDA and EMA continue to facilitate approval routes for new formulations of the MMR vaccine, including combination pediatric vaccination schedules that consolidate multiple injections into fewer injections which enhances compliance.
   
• Lastly, the global MMR vaccine market is poised for continued expansion, driven by increased funding from international health organizations, development of novel adjuvanted and recombinant formulations, and the integration of MMR vaccines into broader maternal and child health initiatives across the globe.
   

Measles, Mumps, Rubella Vaccine Market Analysis

In 2021, the global market was valued at USD 1.6 billion. The following year, it saw a slight increase to USD 1.7 billion, and by 2023, the market further climbed to USD 1.8 billion.
 

Based on the vaccines type, the market is segmented into monovalent, trivalent (combined MMR), and tetravalent. The global market was estimated at USD 2 billion in 2024. The tetravalent segment dominated the market with USD 949 million in 2024.  
 

• The tetravalent segment is gaining traction in the global MMR vaccine market. This segment is fueled by the increasing demand for combination vaccines which aid in decreasing the number of injections, thereby improving compliance, particularly in children.
   
• Tetravalent vaccines facilitate the adherence to vaccination schedules and are rapidly being incorporated into national immunization programs in both developed and emerging economies. Their extended coverage adds convenience and improves uptake in regions aiming for comprehensive control of childhood infectious diseases.
   
• The ongoing attempt to eliminate measles and rubella, coupled with the increasing prevalence of varicella, is driving the demand for MMRV formulations.
   
• In addition, the improved cold-chain infrastructure alongside the WHO's stance is probable to increase the use of tetravalent vaccines globally, making it a key growing segment in the MMR vaccine market.

Based on targeted population, the measles, mumps, rubella vaccine market is divided into infants and children, and adults. The infants and children segment accounted for significant market share of 71.4% in 2024.  
 

• The infants and children segment represents the largest share in the global MMR vaccine market due to routine immunization policies and high vulnerability in early life.
   
• WHO states that over 83% of the world’s infants had received their first dose of MMR vaccine in 2023; however, approximately 22 million children remained unvaccinated. Asian and African nations are scaling up their immunization efforts to reach the WHO 95% coverage target.
   
• The CDC states that two doses of MMR vaccine have a 97% effectiveness against measles, thus making pediatric immunization important. With UNICEF reporting that over 60% of MMR campaigns are aimed at children under five, this market segment is critical for growth. Combination vaccine advancements and ongoing research are projected to further enhance the contribution of these demographics.
   

Based on end use, the measles, mumps, rubella vaccine market is divided into hospitals and clinics, government and public health programs, and other end user. The hospitals and clinics segment dominated the market in 2024 and is expected to reach 2.1 billion by 2034.   
 

• The hospitals and clinics segment holds a dominant position in the global MMR vaccine market due to their participation in immunization programs and the pediatric services provided.
   
• These institutions are the main centers for vaccine delivery in both urban and semi-urban territories. Their established cold chain systems and trained personnel ensure effective vaccine storage and delivery.
   
• In addition, many countries use the hospital framework for mass immunization during epidemic outbreaks which improves this segment’s market share. The increasing number of primary healthcare centers and public-private partnerships in emerging markets also strengthens this segment.

The North America measles, mumps, rubella vaccine market held the largest market share of 40.5% in 2024 in the global market, and it is anticipated to expand at 8.2% CAGR over the forecast period. The U.S. market was valued at USD 726.1 million in 2024.
 

• The U.S. MMR vaccine market is mature and tightly regulated, driven by CDC recommendations and school immunization mandates.
   
• Public Health campaigns have emerged due to localized outbreaks caused by vaccine hesitancy in certain groups, although pediatric vaccination coverage remains high.
   
• The constant controlled pricing and government funding along with policies such as Vaccines for Children (VFC) enhance the market, but there is continual pressure on costs.
   
• Technological innovation is less of a focus compared to access and compliance monitoring systems. The U.S. also plays a major role in global vaccine development and exports, reinforcing its leadership in immunization strategies.
   

The Germany measles, mumps, rubella vaccine market is experiencing robust growth in Europe market.  
 

• Germany’s MMR vaccination market is influenced by federal health system and STIKO (Standing Committee on Vaccination) policies. Vaccination is recommended as well as now mandated since 2020 for school and daycare children.
   
• The market includes multiple suppliers such as GlaxoSmithKline and Merck, with some biosimilar interest on the rise. Germany is known for high vaccine uptake. However, there are some communities with anti-vaccine sentiment which makes things difficult.
   
• Moreover, controlled spending by government through reimbursement and central procurements keeps control over vaccine costs. The country's biopharmaceutical manufacturing infrastructure assures steady domestic supply.
   
• Further, market growth is supported by ongoing modernization of public health infrastructure and emphasis on pandemic preparedness, in which routine immunizations such as MMR are seen as foundational.
   

The Asia Pacific measles, mumps, rubella vaccine market is witnessing substantial growth of 8.6% during the analysis period.
 

• The Asia-Pacific MMR vaccine market is diverse and segmented, reflecting disparities in healthcare access, policy enforcement, and public awareness across countries.
   
• Countries including Australia, South Korea and Japan have stable demand and higher usage stemming from comprehensive national immunization programs. On the other hand, there are still some rural areas in parts of India and Southeast Asia that deal with a lack of access to vaccines and cold chain systems.
   
• This market is sensitive to price and offers a high volume of sales. Key players in the field include Serum Institute of India and other local and multinational marketers. Government policies such as India’s Mission Indradhanush are also improving utility. Meanwhile, public-private partnerships and international funding (e.g., Gavi) are expanding coverage.
   
• The market sees active growth due to population density, urbanization, and rising health expenditure. There's increasing interest in thermostable vaccine formulations suited for resource-limited settings.
   

The Brazil measles, mumps, rubella vaccine market is experiencing robust growth in Latin America market.
 

• Brazil’s MMR vaccine market relies on the public healthcare system which grants free vaccines through the National Immunization Program. The country achieved universal coverage before, but concerns are being raised due to misinformation and logistical issues.
   
• Fiocruz and Instituto Butantan are notable domestic producers, sometimes collaborating with global firms. The government heavily subsidizes production and distribution, which supports widespread accessibility even in remote regions.
   
• Brazil also invests in vaccine research and development and has the capacity to scale domestic production, giving it resilience in global supply disruptions. Market challenges include maintaining cold chain infrastructure and restoring public trust.
   
• Strategic emphasis is on digital health integration, routine catch-up campaigns, and countering anti-vax movements through educational outreach and transparent data sharing.
   

The Saudi Arabia measles, mumps, rubella vaccine market is witnessing substantial growth in Middle East and Africa during the analysis period.
 

• The centralization of healthcare governance under the Ministry of Health greatly enforces the mandated vaccinations for school and Hajj pilgrims, thus serves as a driver for Saudi Arabia'S MMR vaccine market.
   
• Magnificent levels of rural and urban centralization improve the efficiency of immunization. New strategies have been made to align with the goals of Vision 2030, which include increased local pharmaceutical manufacturing and enhanced participation from the private sector.
   
• The market experiences moderate and stable growth, primarily driven by investment in healthcare, population growth, and increased health consciousness among the public. Vaccine awareness campaigns often integrate religious and cultural messaging for greater impact. 
   

Measles, Mumps, Rubella Vaccine Market Share

The top 5 companies in the measles, mumps, and rubella (MMR) vaccine market such as Merck, GSK, Sanofi, Serum Institute of India, and Biological E. account for approximately 75% of the global market share. These firms maintain leadership through scale-driven manufacturing, pediatric-focused immunization programs, and global supply partnerships. Merck and GSK dominate in high-income countries with standardized, combination vaccines supported by robust cold-chain networks.
 

Serum Institute and Biological E lead in affordable MMR formulations tailored for developing regions, often supported by Gavi and UNICEF procurement. Sanofi integrates MMR within broader childhood immunization portfolios across Latin America and Africa. Meanwhile, regional producers such as Beijing and Shanghai Institutes, Minhai Bio, Sinovac, and Zydus Life Science are expanding capacity to meet domestic mandates. With rising government funding, immunization campaigns, and WHO-backed initiatives, global access and uptake continue to strengthen.
 

Measles, Mumps, Rubella Vaccine Market Companies

Major players operating in the measles, mumps, rubella vaccine industry are:

• Actizapharma Pharmaceutical
• Beijing Institute of Biological Products
• Biological E
• GSK
• Merck
• Minhai Bio
• Sanofi
• Serum Institute of India
• Shanghai Institute of Biological Products
• Sinovac
• Zydus Life Science
   
• Merck leads the MMR vaccine market with its flagship product, M-M-R II, the only MMR vaccine licensed in the U.S. Merck’s stronghold lies in its integrated research and development and manufacturing capabilities, bolstered by extensive clinical data and long-term safety records. It supports global immunization through partnerships with public health agencies and ensures cold-chain reliability and timely delivery via advanced distribution systems.
   
• GSK offers MMR vaccines such as Priorix, which is widely used across Europe and international markets. Known for its commitment to high-quality biologics and combination vaccines, GSK brings together robust safety profiles, consistent supply, and ease of administration. The company actively collaborates with national immunization programs and the WHO, helping to secure vaccine equity in middle-income countries. GSK also invests in post-marketing surveillance to continually enhance vaccine effectiveness and safety monitoring.
   
• Serum Institute of India is the world’s largest vaccine producer by volume and a pivotal supplier of WHO-prequalified MMR vaccines. Renowned for its affordable, high-efficacy formulations, Serum Institute supports low- and middle-income countries through UNICEF and Gavi procurement channels. With vertically integrated production, the company ensures scalability and rapid response to global vaccine demand.
   

Measles, Mumps, Rubella Vaccine Industry News

• In January 2025, Serum Institute of India announced a collaboration with Primrose Bio to develop a novel multi-antigen vaccine. This strategic move is expected to enhance its footprint in the global MMR vaccine market.
   
• In March 2023, Merck received FDA approval to add an intramuscular (IM) administration option for its MMRV vaccine in the U.S., expanding beyond the traditional subcutaneous (SC) route and enhancing flexibility in measles, mumps, rubella, and varicella immunization delivery.
   
• In June 2022, GSK’s Priorix received FDA approval, marking the first new U.S. MMR vaccine in 50 years. This approval broadens immunization choices for measles, mumps, and rubella in individuals aged 12 months and older across the nation.
   

The measles, mumps, rubella vaccine market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Vaccines Type

• Monovalent 
• Trivalent (combined MMR)
• Tetravalent

Market, By Targeted Population

• Infants and children
• Adults

Market, By End Use

• Hospitals and clinics
• Government and public health programs
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE